An Economic Evaluation of Stopping Versus Continuing Tumor Necrosis Factor Inhibitor Treatment in Rheumatoid Arthritis Patients With Disease Remission or Low Disease Activity Results From a Pragmatic Open-Label Trial

An Tran-Duy, Marjan Ghiti Moghadam*, Martijn A. H. Oude Voshaar, Harald E. Vonkeman, Annelies Boonen, Philip Clarke, Geoff McColl, Peter M. ten Klooster, T. R. Zijlstra, Willem F. Lems, N. Riyazi, E. N. Griep, J. M. W. Hazes, Robert Landewe, Hein J. Bernelot Moens, Piet L. C. M. van Riel, Mart A. F. J. van de Laar, T. L. Jansen, Dutch Natl POET Collaboration

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1557-1564
Number of pages8
JournalArthritis & Rheumatology
Volume70
Issue number10
DOIs
Publication statusPublished - 1 Oct 2018

Keywords

  • COST-EFFECTIVENESS ANALYSIS
  • MODIFYING ANTIRHEUMATIC DRUGS
  • EULAR RECOMMENDATIONS
  • BIOLOGIC AGENTS
  • DISCONTINUATION
  • THERAPY
  • MANAGEMENT
  • BOOTSTRAP
  • UPDATE

Cite this